Eli Lilly and Co (LLY)

67.85
NYSE : Health Care
Prev Close 67.19
Day Low/High 67.22 / 68.17
52 Wk Low/High 64.18 / 87.20
Avg Volume 5.42M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 74.17B
EPS 2.30
P/E Ratio 29.21
Div & Yield 2.04 (3.00%)

Latest News

Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results

Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results

Lilly's sola study did not reduce amyloid plaques in the brain, adding to the likelihood that Biogen's late-stage Alzheimer's study will prove successful.

Lilly Presents NeoMONARCH Phase 2 Data On Abemaciclib In Early-Stage Breast Cancer

Lilly Presents NeoMONARCH Phase 2 Data On Abemaciclib In Early-Stage Breast Cancer

Abemaciclib - alone or in combination with anastrozole - significantly reduced Ki67 in neoadjuvant HR+/HER2- breast cancer

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies

Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies

This big pharmaceutical player's recent woes could be good news for its rivals, but it also poses risks for investors.

Jim Cramer -- Eli Lilly's Alzheimer Drug Failure Is a Major Disaster

Jim Cramer -- Eli Lilly's Alzheimer Drug Failure Is a Major Disaster

Eli Lilly built up much false hope by being far too bullish on its now-failed Alzheimer treatment, Cramer said.

C, AAPL, FB: Jim Cramer's Views

C, AAPL, FB: Jim Cramer's Views

Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.

Can't Keep This Market Down; Not Too Late to Get In: Jim Cramer's Best Blogs

Can't Keep This Market Down; Not Too Late to Get In: Jim Cramer's Best Blogs

Jim Cramer ponders how this market simply can't stay down and also discusses how it isn't too late to get in.

Allergan Could Pay $1 Billion for Chase Pharma

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Jim Cramer's 'Mad Money' Recap: What You Can Learn From My Portfolio Mistakes

Jim Cramer's 'Mad Money' Recap: What You Can Learn From My Portfolio Mistakes

Cramer has learned what works and what doesn't at Action Alerts PLUS. Here's how his thinking can help you profit.

In Case You Missed It Wednesday: Biotech Drags on Nasdaq as Dow Sets Record

In Case You Missed It Wednesday: Biotech Drags on Nasdaq as Dow Sets Record

Eli Lilly said Wednesday that its experimental drug solanezumab failed to improve cognition of patients with mild Alzheimer's disease in a large Phase 3 clinical trial.

Dow Scores Another Record as Fed Signals a Rate Hike Could Be Coming

Dow Scores Another Record as Fed Signals a Rate Hike Could Be Coming

The Dow closed higher after the minutes from the Federal Reserve's policy-setting meeting indicate that an interest rate hike could come 'relatively soon.'

Dow Clings to Record as Fed Indicates a Rate Hike Could Be Coming

Dow Clings to Record as Fed Indicates a Rate Hike Could Be Coming

The Dow remains higher after the minutes from the Federal Reserve's policy-setting meeting indicate that an interest rate hike could come 'relatively soon.'

On the Hunt for Holiday Movers

On the Hunt for Holiday Movers

I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.

How to Trade Lilly, Deere and Other Most-Active Stocks Wednesday

How to Trade Lilly, Deere and Other Most-Active Stocks Wednesday

Here's a technical look on how to trade some of the most active stocks on the market today.

Cramer: Just When You Thought It Was Too Late to Get In … It Isn't

Cramer: Just When You Thought It Was Too Late to Get In … It Isn't

These 'wing and a prayer' stocks are full of surprises.

Eli Lilly: Is There Life After a Big Gap to the Downside?

Eli Lilly: Is There Life After a Big Gap to the Downside?

It will likely take several months of base building before LLY looks better on the charts.

Dow Hits Intraday Record but Biotech Stocks Weigh on Markets

Dow Hits Intraday Record but Biotech Stocks Weigh on Markets

Stocks trade mixed Wednesday as biotech shares tumble following a sharp drop in shares of Eli Lilly.

Stocks Retreat From Record Highs; Deere Shares Surge on Earnings

Stocks Retreat From Record Highs; Deere Shares Surge on Earnings

U.S. stocks pulled back Wednesday, from their record highs on Tuesday, when the Dow Jones Industrial Average crossed 19,000 and the S&P 500 topped 2,200.

Eli Lilly (LLY) CEO Lechleiter 'Disappointed,' after Alzheimer's Drug Fails

Eli Lilly (LLY) CEO Lechleiter 'Disappointed,' after Alzheimer's Drug Fails

Current Eli Lilly (LLY) CEO John C. Lechleiter and incoming CEO David Ricks reacted to the phase three testing failure of the company's Alzheimer's drug.

Stock Futures Mixed as Durable Goods Orders Climb

Stock Futures Mixed as Durable Goods Orders Climb

Stock futures fluctuate on Wednesday morning after a sharp increase in durable goods orders in October.

Eli Lilly's Alzheimer's Drug Fails Key Clinical Trial

Eli Lilly's Alzheimer's Drug Fails Key Clinical Trial

Based on the negative study results, Lilly will not pursue regulatory approvals for solanezumab in Alzheimer's disease.